Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Revenue (2025 - 2026)

Kura Oncology has reported Revenue over the past 2 years, most recently at $18.3 million for Q1 2026.

  • Quarterly Revenue rose 29.47% to $18.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $71.6 million through Mar 2026, changed N/A year-over-year, with the annual reading at $67.5 million for FY2025, 25.24% up from the prior year.
  • Revenue was $18.3 million for Q1 2026 at Kura Oncology, up from $17.3 million in the prior quarter.
  • Over five years, Revenue peaked at $20.8 million in Q3 2025 and troughed at $14.1 million in Q1 2025.